Stargardt Disease (original) (raw)
Latest News for: stargardt disease
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 (Form 6-K) (Belite Bio Inc)
Public Technologies 15 Jun 2026
of Stargardt Disease Type 1 ... "Stargardt disease places a profound burden on patients, often affecting them early in life and steadily diminishing central vision during critical years of education and independence," said Dr.
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
Hastings Tribune 19 May 2026
Tinlarebant is the first therapeutic candidate to ...
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment ...
Business Wire 05 May 2026
... provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization.
Ascidian Completes Dose Escalation Portion of Phase 1/2 STELLAR Trial of ACDN-01 for Stargardt Disease ...
The Eagle-Tribune 04 May 2026
STELLAR to begin enrolling pediatric subjects ... .
Ascidian Completes Dose Escalation Portion of Phase 1/2 STELLAR Trial of ACDN-01 for Stargardt Disease and Announces Expanded Clinical Study Plans
PR Newswire 04 May 2026
... of Stargardt disease, performs in vivo RNA exon editing and restores full-length ABCA4 protein that is deficient in Stargardt disease – without modifying the genome or introducing foreign enzymes.
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease (Form 6-K) (Belite Bio Inc)
Public Technologies 21 Apr 2026
Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease · Belite expects to complete the new drug application submission in the second quarter of 2026 ... "Stargardt ...
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease (Belite Bio Inc)
Public Technologies 21 Apr 2026
Food and Drug Administration (FDA) for tinlarebant, an investigational novel oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disorder caused by mutations in the ABCA4 gene.
Uncovering mitochondrial defects in photoreceptors opens therapeutic opportunities for Stargardt disease
PNAS 15 Apr 2026
SignificanceStargardt disease type 1 (STGD1) is a progressive ...
Stargardt Disease Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight ...
GetNews 30 Mar 2026
“Stargardt Disease Pipeline Insight, 2026" ... Stargardt Disease current marketed and Stargardt Disease emerging therapies ... Stargardt Disease market drivers and Stargardt Disease market barriers.
VeonGen Announces Clinical Progress of VG801 Gene Therapy in Stargardt Disease, with an Oral
Hastings Tribune 25 Mar 2026
VG801 shows encouraging preliminary efficacy in the ongoing ...
VeonGen Announces Clinical Progress of VG801 Gene Therapy in Stargardt Disease, with an Oral Presentation ...
Nasdaq Globe Newswire 25 Mar 2026
.